Clinical Trials
101
9 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1965
Active, not recruiting
7
6.9%
Completed
69
68.3%
Enrolling By Invitation
1
1.0%
Not yet recruiting
1
1.0%
Recruiting
17
16.8%
Terminated
4
4.0%
Withdrawn
2
2.0%
No approval data available
- The Florida Legislature has allocated $2 million to expand FIU's myFORCE program, which personalizes cancer treatment by testing FDA-approved drugs directly against a patient's own tumor cells. - Led by Dr. Diana Azzam, the program previously demonstrated an 83% improvement rate in children with difficult-to-treat cancers in a Nature Medicine-published study conducted with Nicklaus Children's Hospital. - The funding will support core operations, laboratory teams, data analysis, and expansion of the clinical trials network to enable larger multi-institutional studies. - The functional precision medicine approach is particularly valuable for patients with relapsed or treatment-resistant cancers who have exhausted standard therapies.
- Florida Atlantic University, Brown University, and Florida International University received a five-year, $3.8 million NIH grant to develop new antimalarial drugs targeting the PfGARP protein. - The project builds on the discovery that antibodies against PfGARP trigger apoptosis in Plasmodium falciparum parasites within 12 to 24 hours, independent of other immune cells. - Researchers will use high-throughput screening to identify small molecules that mimic parasite-killing antibodies, creating a novel mechanism-based strategy to combat drug-resistant malaria. - Malaria caused approximately 263 million cases and nearly 600,000 deaths globally in 2023, with over 90% of fatalities occurring in sub-Saharan Africa and children under five disproportionately affected.
- A new study from FIU's Center for Children and Families found that parents experiencing higher stress levels are more likely to use screens to calm or occupy children ages 4 to 8. - Parents with emotional distress were less likely to enforce consistent screen-time limits, while those overwhelmed by child behavior used screens to manage difficult moments. - Researchers recommend focusing on screen time quality over quantity, aligning with American Academy of Pediatrics guidance on meaningful, age-appropriate media. - The study, published in Family Relations, surveyed 822 U.S. caregivers and emphasizes supporting caregivers as much as children in developing healthy media habits.
- The NRG-BN001 Phase II trial demonstrated that proton therapy at 75 Gy improved overall survival in newly diagnosed glioblastoma patients compared to standard photon therapy. - Proton therapy showed a hazard ratio for death of 0.81 with absolute survival benefits of 6.8% at two years and 4.6% at three years. - The treatment reduced severe lymphopenia rates to 17.1% versus 23.4% with photon therapy, potentially preserving immune function critical for anti-tumor response. - These promising results have met the predefined threshold for advancement to a definitive Phase III randomized trial to confirm the therapeutic advantage.
- Florida becomes the first state to offer comprehensive newborn genetic screening through the Sunshine Genetics Pilot Program, providing free genetic sequencing to identify serious but treatable conditions before symptoms appear. - The initiative receives $7.5 million in state funding plus an additional $2 million from Florida State University, establishing the Institute for Pediatric Rare Diseases as the program's central hub. - The Sunshine Genetics Consortium unites Florida's top universities including FSU, UF, UM, USF, and FIU with hospitals and biotech companies to accelerate research and improve access to treatments for rare childhood diseases. - The program aims to end the "Diagnostic Odyssey" that families endure when seeking answers about rare diseases, with early diagnosis enabling proactive care and better outcomes for affected children.
- First Ascent Biomedical's xDRIVE Drug Prediction Platform, showing 83% improvement in treatment outcomes, receives funding from Florida Cancer Innovation Fund to expand personalized cancer care access. - The AI-powered platform combines DNA/RNA sequencing, drug sensitivity testing, and machine learning to identify optimal treatments for cancer recurrence, with notable success in pediatric oncology. - The grant will support expanding treatment access to rural and minority communities in Florida, while advancing FDA Breakthrough Device Designation and insurance coverage approvals.
- Miami Cancer Institute reports significant progress in cancer treatment through precision medicine and AI integration, revolutionizing patient care through comprehensive genomic testing and personalized treatment approaches. - Stage IV lung cancer survival rates have dramatically improved over two decades, with median overall survival extending from 12 months to 2.5 years and five-year survival rates quadrupling to 20%. - Strategic partnerships with Florida International University and global cancer centers are accelerating translational research and advancing innovative therapeutic strategies in oncology.
